The following is a summary of some of the key studies on cognitive dysfunction in multiple sclerosis presented at this year’s European Academy of Neurology virtual congress.
Latest News
SPMS: new data and developments
June 2, 2020Click here to take the SPMS Management survey
A number of recent studies have provided important insights on the pathophysiology, clinical course and treatment of secondary-progressive multiple sclerosis (SPMS). SPMS is generally characterized as a progressive accumulation of disability after an initial relapsing course; further modifiers are active disease (relapses and/or new MRI lesions) with or without progression, not active with progression and not active and no progression (stable disease) (Lublin et al. Neurology 2014;83:278-286).
Slide deck: COVID-19 – Epidemiology in Canada (May 28, 2020)
May 28, 2020Summary of epidemiology, testing and mortality rate; Canada and world statistics.
Sun exposure and MS: effects beyond vitamin D
May 26, 2020Two Swedish case-control studies have reported that the benefits of sun exposure in MS patients occur largely independently of vitamin D (Hedstrom et al. J Neurol 2020;267:1045-1052). The finding has particular relevance during the current COVID-19 pandemic as patients self-isolate indoors.